{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:06:47Z","timestamp":1791410807807,"version":"4.3.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-024-04321-z","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T05:16:41Z","timestamp":1731129401000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Efficacy and safety of inclisiran versus PCSK9 inhibitor versus statin plus ezetimibe therapy in hyperlipidemia: a systematic review and network meta-analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Shengxuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qilan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,9]]},"reference":[{"issue":"1","key":"4321_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12944-019-1171-8","volume":"19","author":"YS Yao","year":"2020","unstructured":"Yao YS, Li TD, Zeng ZH. Mechanisms underlying direct actions of hyperlipidemia on myocardium: an updated review. Lipids Health Dis. 2020;19(1):23.","journal-title":"Lipids Health Dis"},{"issue":"6","key":"4321_CR2","doi-asserted-by":"publisher","first-page":"e051121189015","DOI":"10.2174\/1573403X16999201210200342","volume":"17","author":"A Alloubani","year":"2021","unstructured":"Alloubani A, Nimer R, Samara R. Relationship between Hyperlipidemia, Cardiovascular Disease and Stroke: a systematic review. Curr Cardiol Rev. 2021;17(6):e051121189015.","journal-title":"Curr Cardiol Rev"},{"issue":"1","key":"4321_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","volume":"5","author":"P Libby","year":"2019","unstructured":"Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, Tokgozoglu L, Lewis EF. Atherosclerosis. Nat Rev Dis Primers. 2019;5(1):56.","journal-title":"Nat Rev Dis Primers"},{"issue":"9 Suppl","key":"4321_CR4","first-page":"S139","volume":"23","author":"S Karr","year":"2017","unstructured":"Karr S. Epidemiology and management of hyperlipidemia. Am J Manag Care. 2017;23(9 Suppl):S139\u201348.","journal-title":"Am J Manag Care"},{"issue":"2","key":"4321_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","volume":"9","author":"TA Jacobson","year":"2015","unstructured":"Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, McKenney JM, Grundy SM, Gill EA, Wild RA, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1\u2013full report. J Clin Lipidol. 2015;9(2):129\u201369.","journal-title":"J Clin Lipidol"},{"issue":"1\u20132","key":"4321_CR6","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0021-9150(96)06052-2","volume":"130","author":"S Bertolini","year":"1997","unstructured":"Bertolini S, Bon GB, Campbell LM, Farnier M, Langan J, Mahla G, Pauciullo P, Sirtori C, Egros F, Fayyad R, et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis. 1997;130(1\u20132):191\u20137.","journal-title":"Atherosclerosis"},{"issue":"2 Pt 2","key":"4321_CR7","doi-asserted-by":"publisher","first-page":"278","DOI":"10.2165\/00019053-199712020-00018","volume":"12","author":"D Black","year":"1997","unstructured":"Black D, Davidson M, Koren M, Bakker-Arkema R, Tresh P, McLain R, Smith D, Hunninghake D. Cost effectiveness of treatment to National Cholesterol Education Panel (NCEP) targets with HMG-CoA reductase inhibitors. Trial design. PharmacoEconomics. 1997;12(2 Pt 2):278\u201385.","journal-title":"PharmacoEconomics"},{"issue":"9753","key":"4321_CR8","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Cholesterol Treatment Trialists","year":"2010","unstructured":"Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381.","journal-title":"Lancet"},{"issue":"12","key":"4321_CR9","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/S0735-1097(02)02610-4","volume":"40","author":"MH Davidson","year":"2002","unstructured":"Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, Suresh R, Sun S, Veltri EP. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;40(12):2125\u201334.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"4321_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1527-5299.2003.02434.x","volume":"9","author":"RA Kloner","year":"2003","unstructured":"Kloner RA. Zetia (ezetimibe). Congest Heart Fail. 2003;9(2):109\u201310.","journal-title":"Congest Heart Fail"},{"issue":"3","key":"4321_CR11","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ahj.2004.11.023","volume":"149","author":"CM Ballantyne","year":"2005","unstructured":"Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J. 2005;149(3):464\u201373.","journal-title":"Am Heart J"},{"issue":"10","key":"4321_CR12","first-page":"96","volume":"71","author":"K Kashyap","year":"2023","unstructured":"Kashyap K, Bisht K, Dhar M, Mittal K. Atorvastatin-induced myositis and drug-induced Liver Injury. J Assoc Physicians India. 2023;71(10):96\u20138.","journal-title":"J Assoc Physicians India"},{"issue":"5","key":"4321_CR13","doi-asserted-by":"publisher","first-page":"485","DOI":"10.33963\/v.phj.100526","volume":"82","author":"BE Katamesh","year":"2024","unstructured":"Katamesh BE, Mickow AA, Huang L, Dougan BM, Ratrout BM, Nanda S, Vincent A. Overcoming patient reluctance to statin intolerance. Kardiol Pol. 2024;82(5):485\u201391.","journal-title":"Kardiol Pol"},{"key":"4321_CR14","doi-asserted-by":"crossref","unstructured":"Sucato V, Ortello A, Comparato F, Novo G, Galassi AR. Cholesterol-lowering strategies for Cardiovascular Disease Prevention: the importance of Intensive Treatment and the simplification of Medical Therapy. J Clin Med 2024, 13(7).","DOI":"10.3390\/jcm13071882"},{"key":"4321_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.abb.2017.06.001","volume":"625\u2013626","author":"QM Melendez","year":"2017","unstructured":"Melendez QM, Krishnaji ST, Wooten CJ, Lopez D. Hypercholesterolemia: the role of PCSK9. Arch Biochem Biophys. 2017;625\u2013626:39\u201353.","journal-title":"Arch Biochem Biophys"},{"issue":"2","key":"4321_CR16","doi-asserted-by":"publisher","first-page":"115","DOI":"10.33963\/KP.a2023.0030","volume":"81","author":"SJ Nicholls","year":"2023","unstructured":"Nicholls SJ. PCSK9 inhibitors and reduction in cardiovascular events: current evidence and future perspectives. Kardiol Pol. 2023;81(2):115\u201322.","journal-title":"Kardiol Pol"},{"issue":"3","key":"4321_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/MOL.0000000000000919","volume":"35","author":"JL Katzmann","year":"2024","unstructured":"Katzmann JL, Laufs U. PCSK9-directed therapies: an update. Curr Opin Lipidol. 2024;35(3):117\u201325.","journal-title":"Curr Opin Lipidol"},{"issue":"1","key":"4321_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/2047487320941987","volume":"28","author":"R Diaz","year":"2021","unstructured":"Diaz R, Li QH, Bhatt DL, Bittner VA, Baccara-Dinet MT, Goodman SG, Jukema JW, Kimura T, Parkhomenko A, Pordy R, et al. Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. Eur J Prev Cardiol. 2021;28(1):33\u201343.","journal-title":"Eur J Prev Cardiol"},{"key":"4321_CR19","doi-asserted-by":"crossref","unstructured":"Mercep I, Friscic N, Strikic D, Reiner Z. Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9-A Narrative Review. Cardiovasc Ther 2022, 2022:8129513.","DOI":"10.1155\/2022\/8129513"},{"issue":"5","key":"4321_CR20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1358\/dot.2021.57.5.3277083","volume":"57","author":"CE Kosmas","year":"2021","unstructured":"Kosmas CE, Munoz Estrella A, Sourlas A, Pantou D. Inclisiran in dyslipidemia. Drugs Today (Barc). 2021;57(5):311\u20139.","journal-title":"Drugs Today (Barc)"},{"issue":"2","key":"4321_CR21","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40256-023-00568-7","volume":"23","author":"JE Frampton","year":"2023","unstructured":"Frampton JE. Inclisiran: a review in Hypercholesterolemia. Am J Cardiovasc Drugs. 2023;23(2):219\u201330.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"4","key":"4321_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/MOL.0000000000000877","volume":"34","author":"S Giordano","year":"2023","unstructured":"Giordano S, Polimeni A, Esposito G, Indolfi C, Spaccarotella C. Inclisiran: present and future perspectives of a new effective LDL cholesterol-lowering agent. Curr Opin Lipidol. 2023;34(4):133\u201340.","journal-title":"Curr Opin Lipidol"},{"key":"4321_CR23","doi-asserted-by":"publisher","first-page":"1260921","DOI":"10.3389\/fphar.2023.1260921","volume":"14","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Chen H, Hong L, Wang H, Li B, Zhang M, Li J, Yang L, Liu F. Inclisiran: a new generation of lipid-lowering siRNA therapeutic. Front Pharmacol. 2023;14:1260921.","journal-title":"Front Pharmacol"},{"issue":"7","key":"4321_CR24","doi-asserted-by":"publisher","first-page":"e30581","DOI":"10.1002\/jcb.30581","volume":"125","author":"IO Kehinde","year":"2024","unstructured":"Kehinde IO, Akawa O, Adewumi AT, Rabbad AH, Soliman MES. PCSK9 inhibitors as safer therapeutics for atherosclerotic cardiovascular disease (ASCVD): Pharmacophore design and molecular dynamics analysis. J Cell Biochem. 2024;125(7):e30581.","journal-title":"J Cell Biochem"},{"issue":"11","key":"4321_CR25","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.clinthera.2023.06.011","volume":"45","author":"K Cowart","year":"2023","unstructured":"Cowart K, Singleton J, Carris NW. Inclisiran for the treatment of Hyperlipidemia and for atherosclerotic Cardiovascular Disease Risk reduction: a narrative review. Clin Ther. 2023;45(11):1099\u2013104.","journal-title":"Clin Ther"},{"issue":"20","key":"4321_CR26","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.jacc.2024.03.382","volume":"83","author":"MJ Koren","year":"2024","unstructured":"Koren MJ, Rodriguez F, East C, Toth PP, Watwe V, Abbas CA, Sarwat S, Kleeman K, Kumar B, Ali Y, et al. An Inclisiran First Strategy vs Usual Care in patients with atherosclerotic Cardiovascular Disease. J Am Coll Cardiol. 2024;83(20):1939\u201352.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"4321_CR27","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med"},{"issue":"11","key":"4321_CR28","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384.","journal-title":"Ann Intern Med"},{"key":"4321_CR29","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, et al. The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"issue":"8","key":"4321_CR30","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1080\/00325481.2022.2117498","volume":"134","author":"J Underberg","year":"2022","unstructured":"Underberg J, Toth PP, Rodriguez F. LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals. Postgrad Med. 2022;134(8):752\u201362.","journal-title":"Postgrad Med"},{"issue":"12","key":"4321_CR31","doi-asserted-by":"publisher","first-page":"e0295359","DOI":"10.1371\/journal.pone.0295359","volume":"18","author":"TF Imran","year":"2023","unstructured":"Imran TF, Khan AA, Has P, Jacobson A, Bogin S, Khalid M, Khan A, Kim S, Erqou S, Choudhary G, et al. Proprotein convertase subtilisn\/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: a systematic review and meta-analysis. PLoS ONE. 2023;18(12):e0295359.","journal-title":"PLoS ONE"},{"issue":"6","key":"4321_CR32","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.jacl.2023.09.005","volume":"17","author":"J Mulder","year":"2023","unstructured":"Mulder J, Galema-Boers AMH, Roeters van Lennep JE. First clinical experiences with inclisiran in a real-world setting. J Clin Lipidol. 2023;17(6):818\u201327.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"4321_CR33","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12933-022-01511-x","volume":"21","author":"LC Tao","year":"2022","unstructured":"Tao LC, Xu JN, Wang TT, Hua F, Li JJ. Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations. Cardiovasc Diabetol. 2022;21(1):68.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"4321_CR34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","volume":"41","author":"U Laufs","year":"2020","unstructured":"Laufs U, Parhofer KG, Ginsberg HN, Hegele RA. Clinical review on triglycerides. Eur Heart J. 2020;41(1):99\u2013c109.","journal-title":"Eur Heart J"},{"issue":"4","key":"4321_CR35","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1093\/ehjcvp\/pvae025","volume":"10","author":"SG Goodman","year":"2024","unstructured":"Goodman SG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Harrington RA, Jukema JW, White HD, Zeiher AM, et al. Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation. Eur Heart J Cardiovasc Pharmacother. 2024;10(4):342\u201352.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"5","key":"4321_CR36","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11883-024-01199-2","volume":"26","author":"A Agarwala","year":"2024","unstructured":"Agarwala A, Asim R, Ballantyne CM. Oral PCSK9 inhibitors. Curr Atheroscler Rep. 2024;26(5):147\u201352.","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"4321_CR37","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1017\/S0266462323000296","volume":"39","author":"Y Xiang","year":"2023","unstructured":"Xiang Y, Gan L, Du H, Hao Q, Aertgeerts B, Li S, Hu M. Cost-effectiveness of adding ezetimibe and\/or PCSK9 inhibitors to high-dose statins for secondary prevention of cardiovascular disease in Chinese adults. Int J Technol Assess Health Care. 2023;39(1):e53.","journal-title":"Int J Technol Assess Health Care"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-024-04321-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-024-04321-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-024-04321-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T18:01:42Z","timestamp":1731175302000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-024-04321-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,9]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4321"],"URL":"https:\/\/doi.org\/10.1186\/s12872-024-04321-z","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,9]]},"assertion":[{"value":"26 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a systematic review and meta-analysis, ethics approval and consent to participate are not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"629"}}